Tech Company Financing Transactions

Mersana Therapeutics Funding Round

Mersana Therapeutics secured a $21 million Series B venture capital round on 11/9/2005. Investors included F-Prime Capital, ProQuest Investments and Rho Ventures.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

840 Memorial Dr.
Cambridge, MA 02139
USA

Phone

(617) 498-0020

Website

www.mersana.com

Email Address

[email protected]

Overview

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Anna Protopapas

        

Chief Medical Officer

Dirk Huebner

        

Chief Scientific Officer

Timothy Lowinger

        

VP - Bus. Development

Eva Jack

        

VP - Finance

Brian DeSchuytner

        

VP - Manufacturing

Michael Kaufman

        

Browse more venture capital transactions:

Prev: 11/9/2005: Visto venture capital transaction
Next: 11/9/2005: NanoString Technologies venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary